Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease by Armignacco, Orlando et al.
New Microbiologica, 37, 423-438, 2014
Recommendations for the use  
of Hepatitis C virus protease inhibitors  
for the treatment of chronic Hepatitis C  
in HIV-infected persons.  
A position paper of the Italian Association  
for the Study of Infectious and Tropical Diseases
Orlando Armignacco1, Massimo Andreoni2,  
Evangelista Sagnelli3, Massimo Puoti4, Raffaele Bruno5,  
Giovanni Battista Gaeta6, Carlo F. Perno7, Teresa A. Santantonio8, Paolo Bonfanti9, 
Stefano Bonora10, Marco Borderi11, Antonella Castagna12, Antonella d’Arminio Monforte13, 
Andrea De Luca14, Paolo Grossi15, Giovanni Guaraldi16, Franco Maggiolo17,  
Cristina Mussini18, Caterina Sagnelli19, Marcello Tavio20, Carlo Torti21,  
Caterina Uberti-Foppa12, Massimo Andreoni2, Gioacchino Angarano22,  
Andrea Antinori23, Orlando Armignacco1, Giampiero Carosi24, Antonio Chirianni25,  
Giovanni Di Perri26, Massimo Galli27, Adriano Lazzarin12, Giuliano Rizzardini28,  
Evangelista Sagnelli3, Gloria Taliani29
1Infectious Disease Unit, Belcolle Hospital, Viterbo, Italy; 
2Clinic of Infectious Diseases, Tor Vergata University, Rome, Italy; 
3Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Italy; 
4Infectious Disease Unit, A.O. Ospedale Niguarda Ca’ Granda, Milan, Italy; 
5Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy; 
6Viral Hepatitis Unit, Department of Internal Medicine, Second University of Naples, Italy; 
7Department of Experimental Medicine and Biochemical Sciences, University of ‘Tor Vergata’, Rome, Italy; 
8Clinic of Infectious Diseases, University of Bari, Italy; 
9Department of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy; 
10Department of Infectious Diseases of the University of Torino, Amedeo di Savoia Hospital, Torino, Italy; 
11Infectious Diseases Unit, S. Orsola Hospital, University of Bologna, Bologna, Italy; 
12Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; 
13Clinic of Infectious Diseases, S. Paolo Hospital, University of Milan, Italy; 
14Department of Internal and Specialty Medicine, University Infectious Diseases Unit, A.O.U. Senese, Siena, Italy; 
15University of Insubria, Ospedale di Circolo “Fondazione Macchi”, Varese, Italy; 
16Department of Medical and Surgical Sciences for Children & Adults,  
University of Modena and Reggio Emilia, Modena, Italy; 
17Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy; 
18Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy; 
19Department of Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, Italy; 
20Division of Infectious Diseases, A. O. U. Ospedali Riuniti, Ancona, Italy; 
21Unit of Infectious Diseases, University Magna Graecia, Catanzaro, Italy; 
22U.O.C. of Infectious Diseases, University of Bari, A.O.U.Consorziale Policlinico of Bari, Italy; 
23Clinical Department, National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy; 
24Clinic of Tropical and Infectious Diseases, A. O. “Ospedali Civili di Brescia”, Piazzale Spedali Civili, Brescia, Italy; 
25III Division of Infectious Diseases, A. O. Domenico Cotugno, Naples, Italy; 
26Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Italy; 
27III Divisione Malattie Infettive e Tropicali, Università degli Studi di Milano,Ospedale Luigi Sacco, Milano, Italy; 
281st Infectious Diseases Department, “L. Sacco” Hospital, Milan, Italy; 
29Clinic of Infectious and Tropical Diseases, Department of Clinical Medicine, Policlinico Umberto I,  
Sapienza University of Rome, Italy
O. Armignacco et al.424
INTRODUCTION
The efficacy data obtained with boceprevir 
(BCV) and telaprevir (TPV) in persons with 
genotype 1 hepatitis C virus (HCV) infection 
together with current and future drug availa-
bility raise the question of whether HCV pro-
tease inhibitors (PIs) should be used in human 
immunodeficiency virus (HIV)/HCV co-infect-
ed persons. Only the data from two phase II 
pilot studies are available (Sulkowski and Pol, 
et al., 2013; Sulkowski and Sherman KE et al., 
2013). Due to the absence of large studies on 
HIV/HCV co-infected persons, the clinical and 
policy decisions must be based largely on the 
data obtained from HIV-uninfected persons, 
but they should be adjusted according to the 
unique biological and clinical characteristics 
of HCV co-infection in persons living with 
HIV (PLWHIV). For these reasons the Italian 
Association for the Study of Infectious and 
Tropical Diseases has put forward the pres-
ent “Recommendations for the use of Hepatitis 
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The efficacy data obtained with boceprevir and telaprevir for persons with hepatitis C virus (HCV) genotype 1 
infection raise the question of whether HCV protease inhibitors should be used in human immunodeficiency virus 
(HIV)/HCV co-infected persons. The Italian Association for the Study of Infectious and Tropical Diseases has made 
these recommendations to provide the rationale and practical indications for the use of triple anti-HCV therapy in 
persons living with HIV (PLWHIV).
A Writing Committee of experts indicated by the President of the Association and a Consulting Committee con-
tributed to the document. The final draft was submitted to the evaluation of external experts and the text modified 
according to their suggestions and comments. 
Treatment of HCV co-infection should be considered for all HCV RNA positive PLWHIV. Response-guided therapy 
with pegylated interferon and ribavirin is the standard treatment of PLWHIV with infection by HCV genotype 2, 
3, 4, 5 and 6. Boceprevir and telaprevir should be used to treat HCV genotype 1 infection in HIV/HCV co-infected 
patients for 48 weeks on an individual basis, with close monitoring of their efficacy and tolerability with concur-
rent antiretroviral therapy, taking into account potential drug-drug interactions. The decision to treat a patient or 
to wait for better treatment options, or to discontinue treatment should be made on an individual basis taking into 
account pre-treatment variables and the on-treatment HCV RNA kinetics.
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C virus protease inhibitors for the treatment of 
Hepatitis C in HIV-infected persons”. These rec-
ommendations are intended to provide the ra-
tionale and practical indications for the use of 
triple anti-HCV therapy for PLWHIV. 
The recommendations are graded in three lev-
els according to the GRADE system based on 
the evidence available: A (high), B (medium) 
and C (low, based only on expert opinion), with 
3 degrees of strength of the recommendation: 
1 (strong), 2 (medium), 3 (weak) reported in 
brackets for each statement. It should be noted 
that most of the recommendations are based on 
expert opinion because of the lack of conclusive 
evidence on the use of telaprevir and boceprevir 
for PLWHIV. A Writing Commission of experts 
indicated by the President of the Association 
and a Consulting Committee contributed to the 
document. The final draft was then submitted 
to the evaluation of external experts (Reviewing 
Committee) and the text modified according to 
their suggestions and comments.
RATIONALE FOR THE TREATMENT 
OF HEPATITIS C IN PLWHIV
HCV prevalence and mortality in PLWHIV
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pathways, but HCV is more efficiently trans-
mitted through blood and blood products and 
less efficiently transmitted through sexual in-
tercourse (Puoti and Moioli et al., 2012).
For these reasons, in Italy, where the HIV ep-
idemics in the 1980s and 1990s were mainly 
driven by intravenous drug use (IDU), 20-40% 
of PLWHIV are co-infected with HCV. In par-
ticular, in the ICONA cohort (an Italian cohort 
that enrolled more than 10,000 HIV-positive 
HCV-therapy-naïve patients from different 
centers in Italy), the prevalence of anti-HCV 
antibodies (HCV-Ab) was 32.6%, with 2.6% 
also co-infected with the hepatitis B virus 
(HBV). HCV infection is highly prevalent 
among intravenous drug users (87.4%), while 
it is less frequent among individuals infected 
through heterosexual or homosexual inter-
course (11.4% and 6.1%, respectively) (d’Ar-
minio Monforte A for the ICONA cohort. Per-
sonal communication). 
Thus, the prevalence of HCV co-infection is re-
lated to risk factors for HIV. In another large 
Italian cohort (MASTER), 5688/10206 (55.4%) 
patients followed up in 2012 had positive HCV 
RNA: 46% reported IDU as a risk factor, while 
29% were males having sex with males (MSM) 
[Torti C. for the MASTER cohort. Personal 
communication].
After the introduction of combination antiret-
roviral therapy (cART) in 1996, the HIV-related 
mortality declined in PLWHIV, while liver-relat-
ed causes of death (liver decompensation and 
hepatocellular carcinoma) still remain among 
the primary causes of death in PLWHIV (Ioan-
nou et al., 2013). In the ICONA cohort, liver-re-
lated death accounted for 19.4% of all deaths 
(n=624) [d’Arminio Monforte A for the ICONA 
cohort. Personal communication]. HCV is not 
the only liver-related cause of death since other 
factors contributing to this are: HBV co-infec-
tion, alcohol abuse, HIV-induced CD4 depletion 
and diabetes (Ioannou et al., 2013). 
As a consequence, a multi-target clinical strat-
egy has been proposed to decrease liver-relat-
ed morbidity and mortality in PLWHIV. This 
strategy should include: hepatitis B vaccina-
tion and the optimization of dual anti-HIV and 
anti-HBV therapy, screening for and proactive 
treatment of alcohol abuse, optimization of 
cART, management of insulin resistance and 
a prompt diagnosis and treatment of glucose 
intolerance and diabetes (Puoti et al., 2013). 
As HCV co-infection is the leading cause of 
liver disease in PLWHIV, a “screen and treat” 
strategy for HCV co-infection is, at least in 
theory, the most effective measure to decrease 
liver-related mortality in PLWHIV (Puoti et al., 
2013). The impact of HIV co-infection on the 
natural history of hepatitis C is strong, as HIV 
increases the rate of chronicization of acute 
HCV infection and accelerates the progression 
to cirrhosis, liver decompensation and hepato-
cellular carcinoma (Orsetti et al., 2013; Sori-
ano et al., 2007). It has recently been observed 
that in HIV/HCV co-infected subjects advanced 
fibrosis, defined by a liver stiffness measure-
ment >14.6 kPa, is associated with a risk of 
17% of liver decompensation at 2 years (95% 
confidence interval [CI] 13-23%) (Macías et al., 
2013). Despite excellent results of orthotopic 
liver transplantation in HIV-infected patients 
with non-HCV-related liver disease, the results 
are poorer for HIV/HCV co-infected recipients. 
The worse outcome is mainly related to the 
severity of HCV recurrence, with a more fre-
quent occurrence of fibrosing cholestatic hep-
atitis and a more rapid progression of fibrosis 
(Miro et al., 2012; Antonini et al., 2011). Giv-
en the fundamental role of HCV reinfection in 
this setting, a dramatic impact can be expected 
once new and more potent anti-HCV drugs are 
available for use in the pre- and post-transplant 
phase.
Recommendations
1. Liver diseases are important causes of death in 
PLWHIV in Italy. Hepatitis C is the most frequent 
cause of liver disease in PLWHIV. HIV accelerates 
the progression of hepatitis C to cirrhosis, liver 
decompensation and death. All anti-HCV-nega-
tive PLWHIV should be screened for HCV co-in-
fection at least once a year (A1).
2. Treatment of HCV co-infection should be con-
sidered for all HCV RNA-positive patients (A1).
Because of the rapid progression of liver disease, 
the priority for PLWHIV for anti-HCV treatment 
is always very high (B1), but it is highest among 
those with advanced fibrosis, due to the high 
mortality of these patients in the short term (B1).
3. Survival after liver transplant is suboptimal 
in HCV RNA-positive PLWHIV. A specific study 
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protocol set up for the centers participating in 
the HIV transplant program is strongly needed 
(C2); this protocol should also evaluate the im-
plementation of new anti-HCV drugs, including 
compassionate and off-label use whenever appro-
priate (C1).
Benefits of HCV clearance in PLWHIV
HCV co-infection in PLWHIV has been inde-
pendently associated with an increased inci-
dence of diabetes, neurocognitive impairment 
and kidney failure and of pathological hip frac-
tures (Slama et al., 2009; Peters et al., 2012; Lo 
Re et al., 2012; Ciccarelli et al., 2013).
The severity of the liver disease only partly 
explains the HIV/HCV-associated increased 
risk of these conditions (Maalouf et al., 2013). 
There are also controversial data regarding an 
unfavorable impact of HCV co-infection on the 
progression of HIV infection to AIDS and on 
CD4 recovery after cART initiation. 
Several cohort studies, including those per-
formed within the ICONA cohort, showed an 
accelerated progression to AIDS, and two Ital-
ian cohort studies and a meta-analysis of com-
bined data of four AIDS clinical trial group 
studies showed reduced immune recovery 
with ART (Pulido et al., 2012; Hua et al., 2013), 
while other cohort studies did not confirm 
an influence of HCV on the natural history of 
HIV or on its evolution after ART (Pulido et 
al., 2012). 
These discordant results could be due to con-
founders associated with HCV co-infection: 
history of injection drug use, low socioeco-
nomic status, African American ethnicity and, 
finally, discordance between the CD4 counts 
and the percentage of patients with severe liver 
fibrosis (Pulido et al., 2012). 
However, there is clear evidence that HCV 
co-infection increases the liver toxicity of all 
antiretrovirals, including those of the newer 
generations (Borghi et al., 2013), thereby lim-
iting the potential benefits of cART. 
This risk declines once the patient has achieved 
a sustained virological response (SVR) after 
anti-HCV therapy (Uberti-Foppa et al., 2003).
Achieving SVR to anti-HCV treatment with 
pegylated interferon (PEG-IFN) and ribavirin 
(RBV) is associated with an increased overall 
survival due to a decrease in liver-related mor-
tality and also to a decrease in AIDS-related 
and even in AIDS- and liver-unrelated mortal-
ities (Berenguer et al., 2012; Cenderello et al., 
2013]. 
Thus, SVR to anti-HCV treatment is an impor-
tant outcome that can improve the life expec-
tancy and quality of life for PLWHIV.
Recommendation
4. SVR to anti-HCV treatment is an important 
endpoint in the management of HIV/HCV coin-
fected patients because it is associated not only 
with a decrease in liver-related morbidity and 
mortality (A1), but also a better efficacy and 
tolerability of cART (B2) and, presumably, a re-
duced incidence and severity of HIV-related co-
morbidities such as bone and renal disease, neu-
rocognitive impairment and diabetes (C3).
RESULTS OF ANTI-HCV TREATMENT 
WITH PEGYLATED INTERFERON 
AND RIBAVIRIN IN PLWHIV
Unfortunately, only a small proportion of HIV/
HCV co-infected persons are treated with PEG-
IFN + RBV. This is because of the low propen-
sity of HIV-treating physicians to prescribe in-
terferon, or treatment refusal due to the fear 
of the well-known treatment side-effects, or 
because of contraindications and comorbidi-
ties (Kramer et al., 2012). In the Italian MAS-
TER cohort, of the 5688 HIV/HCV co-infected 
patients followed up, only 926 (16.3%) had re-
ceived interferon with or without RBV [Torti 
C for the MASTER cohort. Personal commu-
nication].
Several studies assessed the SVR rate to PEG-IF-
N+RBV in HIV/HCV co-infected patients (Sori-
ano et al., 2007), which overall was lower than 
60% in all the studies and substantially less 
than 50% in PLWHIV infected by HCV geno-
type 1 or 4 (Soriano et al., 2007).
Several national and international guidelines 
indicate response-guided therapy as the best 
way to optimize treatment with PEG-IFN and 
RBV (Figure 1) and this indication should still 
be followed for patients infected by HCV geno-
types 2, 3 or 4 for whom direct-acting antivirals 
(DAAs) are still not available in clinical practice 
(Soriano et al., 2007).
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Recommendation
5. Response-guided therapy with PEG-INF and 
RBV is the standard treatment for PLWHIV in-
fected by HCV genotypes 2, 3, 4, 5 or 6 (B1).
ANTI-HCV THERAPY WITH PROTEASE 
INHIBITORS IN PLWHIV
The treatment of HCV genotype 1 infection in 
PLWHIV is evolving rapidly following the avail-
ability of the first HCV PIs. TPV and BOC were 
approved by the US Food and Drug Administra-
tion in May 2011 for the treatment of chronic 
hepatitis C both for therapy-naïve and PEG-IF-
N+RBV-experienced patients. They are current-
ly used in combination with PEG-IFN+RBV in 
patients infected with HCV genotype 1.
Anti-HCV treatment of therapy-naïve 
PLWHIV
Phase III clinical trials evaluating the safety 
and efficacy of HCV PIs are underway for ther-
apy naïve HIV/HCV co-infected patients. The 
first data from two phase-2 pilot studies on the 
efficacy and tolerability of BOC- and TPV-based 
triple therapy were released in 2013 (Sulkowski 
and Pol, et al., 2013; Sulkowski and Sherman 
KE et al., 2013). The two studies have a major 
limitation: they enrolled a small number of pa-
tients with a high rate of screening failure (50% 
of those screened) with a small proportion of 
patients with advanced fibrosis (F3 and F4 ac-
cording to the METAVIR classification) lower 
than that included in previous studies with 
PEG-IFN + RBV (Soriano et al., 2007).
Nevertheless, in both studies the SVR rate 
was significantly higher with triple therapy 
than with double therapy. Adverse events (AE) 
were similar and even arithmetically better 
than those observed in HCV mono-infection. 
Some data from ongoing real-life studies con-
firmed that the efficacy and tolerability of TPV 
and BOC in PLWHIV are similar to those ob-
served in HIV uninfected persons (Kostman et 
al., 2013; Benito et al., 2013; Martel-Laferriere 
et al., 2013). There is also some evidence of a 
lower incidence of rash and anal discomfort in 
PLWHIV (Kostman et al., 2013; Benito et al., 
2013; Martel-Laferriere et al., 2013). However, 
in an unselected patient population treated in 
a real-life setting in the USA, a 50% incidence 
FIGURE 1 - Response-guided therapy in PLWHIV with HCV non-1 genotypes.
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of severe adverse events (SAE) was reported 
(Cachay et al., 2013). In HIV negative cirrhot-
ic patients enrolled in a large French study, 
a high rate of SAE and liver decompensation 
with related and unrelated death was reported, 
with the highest incidence in patients with low 
platelet counts and albumin levels (Fontaine et 
al., 2013). Although these preliminary data are 
encouraging, these two drugs carry the same 
challenges for PLWHIV as for the HCV mo-
no-infected:
a) complex treatment schedules;
b) high drug costs;
c) heavy pill burden;
d) t.i.d. administration (although a b.i.d. sched-
ule has since been registered for TPV [GU 
Serie Generale n.105 del 7-5-2013]);
e) potential generation, selection and persis-
tence of viral quasispecies associated with 
resistance to the drug used;
f) marked cross-resistance to the same class 
and potential for cross-resistance to newer 
generation drugs of the same class;
g) a higher incidence of side-effects compared 
with double therapy.
In the two pilot studies, treatment was given for 
a fixed duration of 48 weeks. Studies to assess 
the feasibility of response-guided anti-HCV tri-
ple therapy in PLWHIV are ongoing.
Recommendations
6. BOC and TPV should be used ideally in pro-
spective controlled studies in HIV/HCV co-infect-
ed patients (A2). However, in the absence of these 
studies patients should be treated on an individ-
ual basis with close monitoring of the efficacy 
FIGURE 2 - PEG-IFN + RBV + telaprevir triple therapy. Treatment schedule in PLWHIV.
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and safety of anti-HCV treatment and of concur-
rent antiretroviral therapy (C2). 
The treatment risk/benefit ratio is related to the 
incidence and severity of the side-effects, which, 
in HIV-uninfected patients are more severe in pa-
tients with advanced fibrosis or cirrhosis (A1). 
Treatment should generally be avoided in patients 
with a history of ascites or with albumin <3.5 
g/dL or platelets <100,000 μL. (B1) and may be 
considered only for selected patients with hepato-
cellular carcinoma who are candidates for liver 
transplantation (C3).
7. Patients should be adequately counseled re-
garding the side-effects, treatment schedule, pre-
dicted treatment efficacy and the measures to 
improve the cost effectiveness of treatment (i.e. 
futility rules, rash management plan) (B1). Treat-
ing physicians should see the patient frequently 
and be available for any emergency (B1). Treating 
centers should organize a treating team involv-
ing specialists in infectious diseases, nurses and 
other specialists (hepatologists, dermatologists, 
pharmacologists, psychiatrists) with adequate 
human resources and time for the management 
of scheduled and unscheduled visits. (B2).
8. The recommended schedule of triple therapy in 
PLWHIV is: (Figures 3 and 4).
- 12-week triple therapy followed by 36 weeks 
with PEG-IFN + RBV for patients treated with 
TPV (Figure 2) (B2).
- 4-week “lead in” double therapy with PEG-IFN 
+ RBV followed by 44-week triple therapy with 
BOC (Figure 3) (B2).
The HCVRNA levels should be monitored at least 
with the same frequency indicated for HIV un-
infected patients (B1). HCV sequencing to iden-
FIGURE 3 - PEG-IFN + RBV + boceprevir triple therapy. Treatment schedule in PLWHIV.
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FIGURE 4 - Suggested algorithm for HCV genotype1 treatment in 2013 CE.
tify resistance-associated variants is useful only 
for research purposes both for therapy-naive and 
DAA-experienced subjects (C3). The management 
of side-effects should follow the same indications 
given for HIV-uninfected patients (A2).
9. Shorter treatment durations (i.e., 12 week-tri-
ple therapy with TPV followed by 12-week double 
therapy or 4-week “lead in” with double therapy 
followed by 24 weeks of triple therapy with BOC) 
could be considered for patients without cirrho-
sis with very poor tolerability and with undetect-
able HCV RNA at weeks 4 and 12 for patients 
treated with TPV or at weeks 8 and 24 with BOC 
(C2).
10. The same futility rules indicated in the prod-
uct characteristics of TPV and BOC should be ap-
plied for PLWHIV (Figures 2 and 3) (B2).
However, for all the patients showing a virologi-
cal breakthrough during triple therapy (i.e., a con-
firmed increase in HCV RNA of at least 1 log above 
the nadir) immediate withdrawal of TPV and BOC 
is mandatory (B1). Intensive HCV RNA on-treat-
ment monitoring is strongly recommended.
11. The 4-week “lead in” phase has been consid-
ered by many authors as a sensitivity and toler-
ability test to PEG-INF and RBV. It could also 
be applied for TPV, but TPV should be stopped if 
HCV RNA is >100 IU/mL after 4 or 12 weeks of 
triple therapy, as defined in the REALIZE study 
(Zeuzem et al., 2011) (C2). 
In patients with HCV RNA <50 IU/mL after the 
lead-in phase, treatment with PEG-INF and 
RBV should be continued if the patient is thera-
py-naïve and without cirrhosis (C2). 
TPV 1125 mg b.i.d. after a meal with 21g of fat 
could also be considered for PLWHIV (C2).
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12. In the presence of risk factors for SAE, cir-
rhotic patients should be treated in centers with 
extensive expertise in the administration of anti-
viral therapy (B2). Patients for whom anti-HCV 
treatment has been deferred must be monitored 
periodically according to their disease stage to de-
tect any progression of the liver disease and pos-
sibly be reconsidered for treatment (A1).
Treatment of PEG-IFN + RBV-experienced 
PLWHIV
There are currently no conclusive data on the 
efficacy and safety of triple therapy with BOC 
or TPV for PLWHIV without SVR to a previous 
cycle of PEG-IFN and RBV. Recently the prelim-
inary data from two French investigator-driven 
studies on PEG-IFN and RBV-experienced PL-
WHIV have been reported (Cotte et al., 2013; 
Poizot-Martin et al., 2013). The studies used a 
lead-in phase with either anti-HCV protease 
inhibitor, and the rate of HCV RNA undetect-
ability proved to be unaffected by the previous 
treatment response, fibrosis stage and concur-
rent cART and was similar to that reported in 
HIV-uninfected patients. 
However, in HIV-negative subjects the SVR was 
clearly related to the response to the previous 
treatment as it was higher in relapsers and low-
er in null responders.
Recommendations
13. Treatment with BOC and TPV may be con-
sidered for patients who have failed to respond to 
a previous course of PEG-INF and RBV, ideally 
in prospective controlled studies (B2). For null 
responders, triple therapy must be carefully as-
sessed considering the risk/benefit ratio (A2). The 
tolerability and efficacy of the previous treatment 
cycle must be taken into consideration (B1). The 
best candidates are relapsers with good tolerabil-
ity, while the worst are null responders with poor 
tolerability (C2).
14. In PEG-IFN+RBV-experienced patients the 
same schedules, precautions and futility rules in-
dicated for the therapy-naïve should be followed 
(C2).
Treatment of acute Hepatitis C in PLWHIV
In the last 10 years an ongoing epidemic of acute 
HCV infection has been observed in HIV-infect-
ed MSM worldwide (European AIDS Treatment 
Network, 2013). In the ICONA cohort, the in-
cidence rate of HCV infection was 1.2 per 100 
persons per year of follow-up (PYFU) (95% CI 
1.0-1.4), and decreased from 2.7 per 100 PYFU 
in 1997-2000 (95% CI 2.1-3.3) to 0.8 (95% CI 
0.6-1.2) in 2009-2012. The highest incidence 
was observed in IDU (8.8 per 100 PYFU; 95% 
CI 6.5-11.9), followed by MSM (1.4 per 100 
PYFU; 95% CI 1.1-1.7) (Puoti et al., Submitted). 
Recommendations for the treatment of acute 
HCV infection in PLWHIV have been published 
and are currently included in the guidelines of 
The European AIDS Clinical Society (European 
AIDS Treatment Network, 2013). Preliminary 
data on the successful use of TPV-based triple 
therapy for the treatment of acute HCV infec-
tion in PLWHIV have recently been reported 
(Fierer , 2013).
Recommendation
15. Acute HCV infection in PLWHIV should be 
treated according to the EACS guidelines. TPV or 
BOC should be used for the treatment of acute 
HCV mainly in the setting of clinical studies. 
The use of TPV-based triple therapy should be 
evaluated on an individual basis for selected 
cases (i.e., reinfection in patients with advanced 
fibrosis and compensated liver disease or treat-
ment of patients with very poor predictors of 
SVR).
DRUG-DRUG INTERATIONS 
OF BOCEPREVIR AND TELAPREVIR 
WITH ANTIRETROVIRALS
Several drug-drug interaction studies between 
TPV, BOC and antiretrovirals have been pub-
lished as full papers or presented at Interna-
tional Conferences and their results are sum-
marized in Table 1, where clinically significant 
interactions are shown for healthy volunteers 
(Burger et al., 2013; Wilby et al., 2013; Puoti and 
Rossotti et al., 2012; Rhee et al., 2013).
However, there are several “caveats” for the in-
terpretation of these indications:
- It is difficult to interpret results from drug–
drug interaction studies without detailed 
insight into the concentration–response re-
lationships, which for an antiretroviral are 
also dependent on the susceptibility of HIV 
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Table 1B - Drug-drug interactions between antiretrovirals and Boceprevir (BOC).
HIV drug Effect on ART AUC Effect on BOC AUC Can it be used?
FTC, 3TC No data No data Yes (no potential interactions) 
ABC No data No data Yes (even if interactions cannot be excluded)
TDF +5% +8% Yes
EFV +20% -19% No
NVP No data No data No (potential interactions)
ETR -23% +10% Yes
RPV +39% -6% Yes
ATV/r -35% -5% No
LPV/r -34% -34% No
DRV/r -44% -32% No
RAL +1% +7% Yes
DOLU +8% Unknown Yes
ELVI/COBI -16.2%/+2% +13% Yes
MAR +302% Similar to monotherapy Yes, dose: 150 mg bid
FTC: emtricitabine; ABC: abacavir; 3TC: lamivudine; TDF tenofovir; EFV: efavirenz;  NVP: nevirapine;  ETR: etravirine; RPV: rilipivirine; 
ATV/r atazanavir boosted with ritonavir; DRV/r darunavir boosted with ritonavir; LPV/r: lopinavir boosted with ritonavir; FPV/r: fosamprena-
vir boosted with ritonavir; RAL: raltegravir; DOLU dolutegravir; ELVI: elvitegravir; COBI: cobicistat; MAR: maraviroc; TPV: telaprevir; BOC: 
boceprevir; ART: antiretroviral therapy; AUC: area under the curve.
Table 1A - Drug-drug interactions between antiretrovirals and Telaprevir (TPV).
HIV drug Effect on ART AUC Effect on TPV AUC Can it be used?
FTC, 3TC No data No data Yes, no potential interactions
ABC No data No data Yes, although interactions 
cannnot be excluded
TDF +30% 0% Yes
EFV -7% -18% TPV dose 1125 mg q8h Yes
ETR -6% -16% Yes
NVP No data No data No (potential interactions)
RPV +79% -8% Yes
ATV/r +17% -20% Yes
DRV/r -40% -35% No
FPV/r -47% -32% No
LPV/r +6% -54% No
RAL +31% +7% Yes
DOLU +25% Unknown Yes
MAR +949% Similar to monotherapy Yes, dose: 150 mg bid
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to the relative antiretroviral in the individual 
patient.
- Pharmacokinetics studies assess plasma (or 
serum) pharmacokinetic parameters, while 
it is known that anti-HCV agents are primar-
ily active inside the hepatocyte and not in 
plasma.
Despite expected reductions in the levels of plas-
ma drug levels due to drug-drug interactions, 
the above-mentioned pilot study including 55 
patients treated with BOC in combination with 
anti-HIV PIs did not show an increased in-
cidence of virological rebound of HIV during 
BOC exposure or any decrease in SVR to an-
ti-HCV therapy related to the exposure to the 
anti-HIV PI (Sulkowski and Pol et al., 2013).
CONCURRENT ANTIRETROVIRAL 
THERAPY
Patients not taking antiretrovirals
TPV-based triple therapy has been adminis-
tered in 7 patients not taking antiretrovirals, 
with SVR in 5/7. The most important finding 
for these 7 subjects was the absence of resist-
ance mutations in HIV after exposure to TPV 
(Sulkowski and Sherman et al., 2013). Thus, 
for patients with CD4 counts greater than 500 
cells/mL and not receiving antiretrovirals, HCV 
treatment could be considered without starting 
antiretroviral therapy.
However, many guidelines support anti-HIV 
treatment in all HCV co-infected patients inde-
pendently of the CD4 count.
Recommendation
16. Patients with CD4 >500 cells/mL and a stable 
HIV disease not under antiretrovirals can start 
anti-HCV triple therapy directly. However, start-
ing stable ART could also be considered before 
starting anti-HCV treatment as an alternative 
measure for these patients (C2). The time interval 
between starting ART and the start of anti-HCV 
treatment should be at least 8 weeks (C2).
Patients taking antiretrovirals without 
a clinically significant interaction with 
telaprevir and boceprevir
For patients taking effective and tolerated an-
tiretrovirals without a clinically significant 
drug-drug interaction with TPV or BOC, some 
issues should be taken into account: exposure 
to tenofovir is increased by concurrent TPV 
administration, so close monitoring of the re-
nal and tubular functions is mandatory during 
the co-administration of these 2 drugs (Wilby 
et al., 2013). For patients taking efavirenz, TPV 
should be given at 1125 mg t.i.d. (Sulkowski 
and Sherman et al., 2013; Wilby et al., 2012), 
which results in a 50% increase in TPV costs.
Atazanavir C through is increased by the con-
current administration of TPV, so patients 
should be advised of a possible increase in or 
onset of jaundice during the co-administration 
of these drugs (Sulkowski and Sherman et al., 
2013; Wilby et al., 2012), Finally, treatment with 
abacavir has been associated in some studies 
with a reduced efficacy of double therapy based 
on low doses of RBV. Although the data on this 
issue are controversial, this should be taken 
into account when decreasing the RBV dose for 
patients taking abacavir (Puoti and Rossotti et 
al., 201).
Rilpivirine exposure is increased by 79% by con-
current TPV administration. This increase does 
not seem to be associated with an increased in-
cidence of QT interval prolongation, but ECG 
monitoring is advisable for patients taking oth-
er drugs with the potential to increase the QT 
interval (Wilby et al., 2013).
Raltegravir and dolutegravir can be co-admin-
istered safely with BOC and TPV, though the 
pharmacokinetics of raltegravir in HIV-infect-
ed subjects are characterized by both high in-
tra- and inter-patient variability, a condition 
that limits the application of Therapeutic Drug 
Monitoring (TDM) for raltegravir (Cattaneo et 
al., 2012; Johnson et al., 2013). The preliminary 
data did not show any significant interaction 
between TPV and elvitegravir/cobicistat (Cus-
todio et al., 2013).
Recommendation
17. For patients receiving an antiretroviral regi-
men without significant interaction with TPV or 
BOC, cART should be maintained without mod-
ifications (B1), but the renal and tubular func-
tions should be closely monitored in those receiv-
ing TPV and tenofovir without efavirenz (B2). 
The efficacy of anti-HCV therapy should be as-
sessed more frequently in those taking abacavir 
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and receiving a reduced RBV dose because of 
anemia (C2). 
The increased cost of TPV should be taken into 
account for those receiving efavirenz (B1) and 
the increased severity of jaundice for those taking 
atazanavir (C2). 
Drug-drug interaction between antiretrovirals, 
anti-HCV drugs and additional drugs or sub-
stances taken by the patient should be carefully 
evaluated and patients should be advised of po-
tential interactions (B1).
Patients receiving antiretrovirals 
with significant interaction with telaprevir 
and boceprevir
Some authors suggest suspending all antiretro-
virals for the three months of TPV co-adminis-
tration when the clinical history of the patient 
(CD4 nadir, current CD4 counts, treatment his-
tory) does not indicate a contraindication to in-
terrupting ART. However, this option does not 
seem to be feasible for most patients and may 
induce a loss of HIV disease control, which is 
the highest priority for HIV-infected patients. 
For patients with a complex ART history or 
resistance to multiple classes of ART, consulta-
tion with experts regarding the optimal strat-
egy to minimize the risk of HIV breakthrough 
is advised. For these patients, TPV may be the 
preferable HCV NS3 PI because of its shorter 
treatment duration (12 weeks) than BOC (24 to 
44 weeks).
Recommendations
18. For HCV genotype 1 patients taking antiret-
rovirals with significant interaction with BOC 
or TPV who cannot wait for new anti-HCV com-
binations and who show good predictors of re-
sponse to double therapy, there are 2 possible 
solutions:
- Switching the current regimen to another with-
out significant interaction if there are no issues 
regarding the potential efficacy and tolerability of 
the new regimen. The efficacy and tolerability of 
the new regimen should be evaluated for at least 
8 weeks before starting anti-HCV treatment (C2);
- Maintaining the current regimen if the decreased 
or increased exposure to anti-HCV and anti-HIV 
drugs does not seem to be related to a loss of ef-
ficacy or to increased toxicity based on the indi-
vidual patient’s treatment history and HIV resist-
ance profile. In this case intense monitoring of 
HIV RNA and HCV RNA is mandatory and when 
the TDM of the antiretrovirals is available (C2).
FUTURE PERSPECTIVES FOR ANTI-HCV 
TREATMENT IN PLWHIV
The advent of TPV and BOC heralded a new 
era of more effective HCV treatment. There are 
currently more than 50 agents under investiga-
tion in human studies for HCV infection, with 7 
different mechanisms of action directed toward 
the virus and the host (Wilby et al., 2012). Clin-
ical trials with these agents are ongoing in HIV 
co-infected patients and preliminary data on 
drug-drug interactions with antiretrovirals and 
on their efficacy and safety in HIV co-infected 
patients have already been presented for two 
protease inhibitors simeprevir (Dieterich and 
Rockstroh et al., 2013) and faldaprevir (Dieter-
ich and Soriano et al., 2013) and a polymerase 
inhibitor sofosbuvir (Rodriguez-Torres et al., 
2012). There are also ongoing trials with quad-
ruple anti-HCV therapy including asunaprevir 
+ daclatasvir + PEG-IFN + RBV (Pilot Study to 
Assess the Efficacy of and Tolerance to a Quad-
ruple, 2013). This drug development pipeline 
could lead in the future to new anti-HCV treat-
ment schedules, even interferon-free, with a 
single daily dose, fewer adverse effects, potency 
across all HCV genotypes, and reduced selection 
of resistant viral strains, either through the use 
of combinations of agents with different mech-
anisms of action or resistance profiles or the use 
of agents with high individual barriers to resist-
ance. Most importantly, these combinations of 
DAAs might eradicate HCV without the need for 
PEG-IFN. For this reason, the decision to treat 
or not an HIV/HCV co-infected patient with the 
currently available anti-HCV DAAs needs to be 
made taking into account the advantages and 
disadvantages of early versus delayed treatment.
TREATMENT OF HIV/HCV CO-INFECTED 
PATIENTS IN 2013 CE: WAIT OR TREAT?
The first decision regarding an HIV/HCV co-in-
fected patient who is a candidate for anti-HCV 
treatment is: should we wait for upcoming and 
Recommendations for the use of Hepatitis C virus protease inhibitors 435
promising new drugs or should we treat now? 
This decision should be based on 6 points:
1) The urgency of treatment, which is essen-
tially related to the stage of the liver disease, 
taking into account that 20-24% of HIV/HCV 
co-infected patients could progress by 2 Ishak 
stages of fibrosis (or more) in less than 3 years 
and that the vast majority of HIV/HCV co-in-
fected patients contracted HCV more than 20 
years ago.
2) The probability of SVR, which is related to: 
mild fibrosis, low HCV RNA levels (<400,000 
IU/mL), favorable IL28 genetic profile in HCV 
genotypes 1 and 4 and subtype 1b, gender and 
ethnicity. An index is available that allows the 
probability of SVR to PEG-IFN plus RBV to be 
calculated for a single patient. The HCV geno-
type is the strongest predictor of SVR, with the 
lowest probability for genotypes 1 and 4, but if 
the results obtained with BOC and TPV in pilot 
studies on genotype 1 are reproducible in real 
life, only HCV genotype 4 will remain a strong 
predictor of non-response to anti-HCV treat-
ment. A rapid virological response (negativiza-
tion of HCV RNA) after 4 weeks of PEG-IFN 
and RBV is associated with an SVR rate higher 
than 85%. Thus, patients with RVR to double 
therapy could be treated without the addition 
of TPV or BOC. In HCV genotype-1 patients 
without HIV co-infection, a decrease of 1 log 
after 4 weeks of PEG-IFN and RBV treatment 
identifies patients with the highest probability 
of SVR to triple therapy with BOC, as well as 
previous null responders with a significantly 
higher probability of SVR to triple therapy with 
TPV. There are no data on the predictability for 
HIV-infected patients.
3) The presence of relative contraindications, 
and the predicted patient tolerability of the 
side-effects of treatment and treatment com-
pliance with a complex daily schedule with a 
heavy pill burden.
4) The patient’s motivations, which are influ-
enced by social and working conditions, the 
perception of HCV liver disease and propensity 
to treatment. 
5) The interactions between anti-HCV drugs 
and concurrent antiretroviral therapy and the 
possibility of switching to antiretrovirals with-
out significant drug-drug interaction without 
changing the efficacy of stable antiretroviral 
treatment based on drugs that may exert clin-
ically significant interaction with BOC or TPV.
6) The sustainability of the costs of treatment 
by the patient or other party.
The patients should be involved in this decision 
and should receive full information on these 
issues. If controlled trials are available the pa-
tient should also be informed of the same.
Recommendation
19. The decision to treat a patient now or to wait 
for better treatment options should be taken with 
the patient on the basis of (B2):
1. The urgency of treatment.
2. The probability of SVR.
3. The presence of relative contraindications and 
the patient’s predicted tolerability of the side-ef-
fects of treatment and treatment compliance with 
a complex daily schedule with a heavy pill burden.
4. The patient’s motivations.
5. The interactions between anti-HCV drugs and 
concurrent antiretroviral therapy.
6. The sustainability of current treatment options 
and the predicted sustainability of future treat-
ment options.
A practical algorithm for a moving target
Recent phase III data on the efficacy and toler-
ability of sofosbuvir in combination with PEG-
INF and RBV in HCV monoinfection showed 
an overall SVR rate of 90% with an 80% rate in 
HCV therapy-naïve cirrhotics infected by HCV 
genotype 1 (Wilby et al., 2012). The same re-
sponse rate was obtained in registration trials 
in some categories of HIV-uninfected patients 
(Wilby et al., 2012):
- Patients with undetectable HCV RNA after the 
lead-in phase who continued treatment with 
PEG-INF and RBV.
- Patients with undetectable HCV RNA after 4 
weeks of triple therapy treated with PEG-INF 
and RBV plus TPV or BOC.
Recommendations
20. A pragmatic algorithm (Figure 4) could be 
considered in 2013 CE for genotype 1 HCV-HIV 
co-infected patients.
- Treatment could be initiated with PEG-INF and 
RBV for 4 weeks in order to assess the efficacy 
and tolerability of this “backbone” of therapy.
- For those with undetectable HCV RNA and ac-
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ceptable tolerability, continuation of treatment 
with PEG-INF and RBV could be considered fol-
lowing the classic treatment schedule for co-in-
fected patients (C2).
- For those with detectable HCV RNA but with a 
decrease in HCV RNA of at least 1 log and accept-
able tolerability, BOC or TPV could be added (C2).
21. For those without a decrease in HCV RNA of 
at least 1 log and/or with poor tolerability, treat-
ment withdrawal and waiting for a new treat-
ment option could be discussed with the patient 
(C2). For patients with greater urgency of treat-
ment and more advanced fibrosis, the addition of 
BOC or TPV should always be considered (C3).
22. Four weeks after starting treatment with 
PEG-INF + RBV and BOC or TPV:
a. For those with undetectable HCV RNA and ac-
ceptable tolerability, triple therapy could be con-
tinued according to the above-mentioned sched-
ule (C2).
b. For those with detectable HCV RNA and/or 
without acceptable tolerability, treatment with-
drawal should be considered and a watchful 
waiting strategy for newer treatment options 
could be discussed with the patient (C2).
23. For patients with confirmed HCV RNA break-
through (i.e., a one-log increase in the nadir level 
on treatment) or severe side-effects during tri-
ple therapy, treatment withdrawal and watchful 
waiting for new treatment options is mandatory 
(C2).
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